Treatment with the aromatase inhibitor letrozole can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy.
Among women originally in the placebo arm of an international trial of letrozole who chose to begin letrozole treatment after the initial trial was halted, the risk that their cancer would recur was cut in half compared with those who never received letrozole.
...
Post new comment